• Lumiracoxib: Timing COX-2 in Muscle Repair

  2026-08-13

  Lumiracoxib is a selective COX-2 inhibitor useful for testing how inflammatory lipid signaling changes across muscle injury and repair. This article develops a decision-focused assay framework that separates early vascular protection from later proangiogenic remodeling.

• VER 155008: HSP 70 Inhibitor Workflows

  2026-08-13

  Build reproducible VER 155008 workflows across biochemical, cancer-cell, and condensate assays. This guide distinguishes direct Hsp70 ATPase inhibition from downstream apoptosis, client-protein degradation, and stress-dependent TDP-43 phase behavior.

• IPA-3, Pak1 Signaling, and HIV Nuclear Import

  2026-08-12

  IPA-3 is a selective, non-ATP-competitive Pak1 tool for separating kinase-regulatory effects from the CD4–LCK–CDK1 pathway that licenses HIV-1 nuclear import. This article provides an evidence-aware framework for kinase assays, cell signaling studies, and cross-domain interpretation without overstating Pak1 involvement.

• PAD4-IN-2 TFA: Assay-to-Mechanism Guide

  2026-08-12

  PAD4-IN-2 TFA, also known as Compound 5i TFA, connects tumor-selective uptake with inhibition of the PAD4–H3cit–NET axis. This guide explains how to interpret its biochemical, cellular, immune, and in vivo evidence while designing rigorous cancer research assays.

• Fluorescein Tyramide for Circuit-Level Signal Amplification

  2026-08-11

  Fluorescein Tyramide enables localized signal amplification for low-abundance targets in IHC, ISH, and validated flow cytometry workflows. This article translates new oxytocin–superior colliculus findings into practical decisions about assay sensitivity, spatial resolution, and experimental controls.

• BIIE 0246 Workflows for Y2R Signaling

  2026-08-10

  BIIE 0246 is a nanomolar neuropeptide Y Y2 receptor antagonist for separating presynaptic, behavioral, and neuro-adipose signaling mechanisms. This practical guide connects receptor pharmacology with slice, tissue, feeding, anxiety, and cardiac co-culture workflows while clearly distinguishing established evidence from exploratory assay design.

• OSMI-1: A Causal Map for Placental Ferroptosis

  2026-08-09

  OSMI-1 is a cell-permeable O-GlcNAc transferase inhibitor that can dissect the HUWE1–TfR1 pathway linking protein O-GlcNAc modification to trophoblast ferroptosis. This article presents an assay-centered strategy for separating target engagement, iron dysregulation, cellular injury, and syncytialization defects.

• Oligomycin A for Reliable Mitochondrial Assays

  2026-08-08

  Learn how Oligomycin A (SKU A5588) can clarify mitochondrial ATP production, sodium-associated energy failure, metabolic adaptation, and cytotoxicity assay results. This scenario-based guide covers experimental controls, stock preparation, data interpretation, and practical product-selection criteria.

• Fluorouracil (Adrucil): Mechanism & Benchmarks

  2026-08-07

  Fluorouracil, also called 5-Fluorouracil or 5-FU, is a uracil analogue that generates FdUMP and inhibits thymidylate synthase. Product benchmarks include an IC50 of 2.5 μM in HT-29 cells after 7 days and significant tumor-growth inhibition in mice receiving 100 mg/kg intraperitoneally once weekly.

• Baicalein: Mechanistic Insights and Advanced Applications in

  2026-08-07

  Explore the multifaceted role of Baicalein, a potent 12-LOX pathway inhibitor, in apoptosis research and metabolic enzyme regulation. This article provides a mechanistic deep-dive and comparative analysis, revealing how Baicalein's unique properties advance cancer and inflammation studies beyond current protocols.

• AMG 487: Potent CXCR3 Antagonist for Inflammation Research

  2026-08-06

  AMG 487 is a highly selective CXCR3 antagonist that modulates chemokine-driven cell migration and macrophage polarization. Its nanomolar potency against key chemokines and favorable pharmacological profile make it a benchmark tool for dissecting CXCR3-mediated inflammatory signaling. Recent studies confirm AMG 487’s utility in acute lung injury models via context-dependent immune modulation.

• Azilsartan (TAK-536) in Neuroinflammation & RAS Research

  2026-08-06

  Azilsartan (TAK-536) empowers researchers to dissect AT1 receptor signaling with unmatched specificity in both neuroinflammation and cardiovascular models. This guide translates the latest mechanistic advances into actionable workflows, troubleshooting strategies, and comparative insights for robust renin-angiotensin system research.

• NF 449: Mechanistic Precision for Advanced Platelet Inhibiti

  2026-08-05

  Discover how NF 449, a potent purinergic receptor antagonist, enables high-precision mechanistic analysis of platelet aggregation and antithrombotic agent research. This article delivers a unique, in-depth perspective on assay design and translational potential.

• p-tau Ser356 in Alzheimer’s Disease: Insights from NUAK Inhi

  2026-08-05

  This study identifies phosphorylation of tau at Ser356 (p-tau Ser356) as a Braak stage-dependent marker closely associated with neurofibrillary tangle pathology in Alzheimer’s disease. Using pharmacological NUAK1/2 inhibition, the research reveals distinct responses in mouse and human brain slice cultures, highlighting the complexity of targeting tau phosphorylation therapeutically.

• Synergistic Tumor Immunotherapy: LNP-Delivered IL-23 mRNA an

  2026-08-04

  The reference study introduces a combinatorial immunotherapy strategy using lipid nanoparticle-encapsulated circular IL-23 mRNA and platinum-modified STING agonist MSA-2-Pt for enhanced antitumor effects. This approach prolongs local cytokine expression and immune activation while minimizing systemic toxicity, highlighting promising avenues for next-generation cancer immunotherapy.

450 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page